NFKB1 and atopic eczema: Moreover, because PCG inhibits both calcium signaling and ERK/NF-κB pathways downstream of PAR2 activation, it is expected to exhibit greater therapeutic efficacy for atopic dermatitis compared to PAR2 antagonists such as GB88, which exhibit pathway selective inhibition [34].